NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









TCRCure Biopharma

TCRCure Biopharma

Private
Beijing, BeijingHealthcare & Life Scienceshttps://www.tcrcure.com

Last Round

Series B

Feb 16, 2022

Total Funding Raised

$47.3M

Company Overview

TCRCure is a biotechnology company specializing in the development of cancer immunotherapies through advanced techniques such as high throughput antigen-specific TCR cloning, large-scale virus production, T cell genetic engineering, and immune cell manufacturing.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Application

Keywords

TCR-T cell therapyCAR-T cell therapycell therapysolid tumor therapycancer immunotherapyliving drugsT-cell engineeringautologous cell therapyclinical-stage biopharmaTCR discoveryAI drug discoverygene therapyin-house manufacturingdrug discovery platform

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

TCRCure Biopharma Comps

Public and private peers based on sector, stage, and business model.

TCRCure Biopharma comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

TCRCure Biopharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BFeb 16, 2022
Series BDec 28, 2018
Series AApr 1, 2018
View all Funding Rounds

Key People

Founding team and executive leadership

Si Li

Chief Technology Officer

Executive Team

TCRCure Biopharma Investors

Notable investors and investment history

TCRCure Biopharma investors
InvestorRounds
Emerging Technology PartnersSeries B
CCB Financial Assets InvestmentSeries B
德同资本Series B
Share CapitalSeries B
Founder Hesheng Investment Co., Ltd.Series B
View all Investors

TCRCure Biopharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

TCRCure Biopharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about TCRCure Biopharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersBeijing, Beijing
Employee Range17
Year Founded2016
Last FundingFeb 16, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.